ABUS:NASDAQ
Arbutus Biopharma Corp
$4.09
arrow_upward
+1.49%(+0.060) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABUS...
Open
$4.04
High
$4.14
Low
$3.92
Mkt. cap
626.97M
Avg. vol.
3.23M
Volume
3.31M
P/E ratio
3.65
52-wk high
$5.45
52-wk low
$3.50
EPS
$1.12
Beta
0.84
Shares outstanding
153.29M
No. of employees
19
Open
$4.04
High
$4.14
Low
$3.92
Mkt. cap
626.97M
Avg. vol.
3.23M
Volume
3.31M
P/E ratio
3.65
52-wk high
$5.45
52-wk low
$3.50
EPS
$1.12
Beta
0.84
Shares outstanding
153.29M
No. of employees
19
News stories
From web sources and news partners
BigGo Finance
·
9 hours ago
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
Benzinga
·
1 hour ago
Dow Jones, Nasdaq 100, and S&P 500 Outlooks: Key Stock Market News This Week
The Motley Fool
·
3 hours ago
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
Traders Union
·
6 hours ago
Chris Ciovacco: Semiconductors SMH and S&P 500 SPY show several possible support areas
Profile
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
About Arbutus Biopharma Corp
CEOWilliam H. Collier
Employees19
Founded2007
HeadquartersWarminster Township, Pennsylvania, United States
SectorHealth Care
IndustryBiotechnology
Websitearbutusbio.com